What is William Blair’s Forecast for PRCT FY2025 Earnings?

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) – Equities research analysts at William Blair cut their FY2025 EPS estimates for shares of PROCEPT BioRobotics in a research note issued to investors on Wednesday, November 5th. William Blair analyst B. Vazquez now forecasts that the company will earn ($1.51) per share for the year, down from their prior estimate of ($1.49). The consensus estimate for PROCEPT BioRobotics’ current full-year earnings is ($1.75) per share. William Blair also issued estimates for PROCEPT BioRobotics’ Q4 2025 earnings at ($0.33) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.27) EPS, Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($1.01) EPS.

Several other equities analysts have also recently issued reports on PRCT. Morgan Stanley reduced their price objective on PROCEPT BioRobotics from $71.00 to $68.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 15th. Oppenheimer upgraded shares of PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a research report on Tuesday, September 2nd. Piper Sandler reaffirmed an “overweight” rating and set a $50.00 price objective (down previously from $55.00) on shares of PROCEPT BioRobotics in a research report on Wednesday. TD Cowen dropped their price objective on shares of PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Wednesday, October 8th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, PROCEPT BioRobotics presently has an average rating of “Moderate Buy” and an average target price of $63.30.

PROCEPT BioRobotics Price Performance

Shares of PRCT opened at $31.92 on Friday. PROCEPT BioRobotics has a 52 week low of $29.78 and a 52 week high of $103.81. The company has a current ratio of 8.44, a quick ratio of 7.86 and a debt-to-equity ratio of 0.14. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -20.86 and a beta of 0.98. The stock has a 50 day moving average of $36.02 and a 200-day moving average of $47.66.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. PROCEPT BioRobotics had a negative return on equity of 21.72% and a negative net margin of 28.20%.The business had revenue of $83.33 million during the quarter, compared to the consensus estimate of $80.78 million. During the same period last year, the firm earned ($0.40) earnings per share. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS.

Institutional Trading of PROCEPT BioRobotics

Several large investors have recently added to or reduced their stakes in the business. Alliancebernstein L.P. boosted its position in PROCEPT BioRobotics by 0.6% during the 2nd quarter. Alliancebernstein L.P. now owns 2,156,856 shares of the company’s stock worth $124,235,000 after acquiring an additional 13,163 shares during the period. Westfield Capital Management Co. LP raised its stake in shares of PROCEPT BioRobotics by 113.5% during the second quarter. Westfield Capital Management Co. LP now owns 1,598,349 shares of the company’s stock valued at $92,065,000 after purchasing an additional 849,792 shares in the last quarter. Chicago Capital LLC lifted its holdings in PROCEPT BioRobotics by 175.7% in the third quarter. Chicago Capital LLC now owns 1,568,845 shares of the company’s stock worth $55,992,000 after purchasing an additional 999,873 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in PROCEPT BioRobotics by 43.6% in the first quarter. T. Rowe Price Investment Management Inc. now owns 1,415,403 shares of the company’s stock worth $82,462,000 after purchasing an additional 429,461 shares during the period. Finally, Geode Capital Management LLC grew its position in PROCEPT BioRobotics by 9.7% in the 2nd quarter. Geode Capital Management LLC now owns 1,298,894 shares of the company’s stock valued at $74,826,000 after buying an additional 115,229 shares in the last quarter. 89.46% of the stock is currently owned by institutional investors and hedge funds.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).